ZA200708906B - Use of RIP in treating staphylococcus aureus infections - Google Patents

Use of RIP in treating staphylococcus aureus infections

Info

Publication number
ZA200708906B
ZA200708906B ZA200708906A ZA200708906A ZA200708906B ZA 200708906 B ZA200708906 B ZA 200708906B ZA 200708906 A ZA200708906 A ZA 200708906A ZA 200708906 A ZA200708906 A ZA 200708906A ZA 200708906 B ZA200708906 B ZA 200708906B
Authority
ZA
South Africa
Prior art keywords
rip
staphylococcus aureus
aureus infections
treating staphylococcus
treating
Prior art date
Application number
ZA200708906A
Other languages
English (en)
Inventor
Balaban Naomi
Original Assignee
Balaban Naomi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balaban Naomi filed Critical Balaban Naomi
Publication of ZA200708906B publication Critical patent/ZA200708906B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200708906A 2005-04-04 2006-04-04 Use of RIP in treating staphylococcus aureus infections ZA200708906B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66813205P 2005-04-04 2005-04-04

Publications (1)

Publication Number Publication Date
ZA200708906B true ZA200708906B (en) 2009-01-28

Family

ID=37074030

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708906A ZA200708906B (en) 2005-04-04 2006-04-04 Use of RIP in treating staphylococcus aureus infections

Country Status (9)

Country Link
US (1) US7824691B2 (xx)
EP (1) EP1871405A4 (xx)
JP (1) JP2008534686A (xx)
CN (1) CN101175507A (xx)
AU (1) AU2006231494A1 (xx)
CA (1) CA2603805A1 (xx)
IL (1) IL186375A0 (xx)
WO (1) WO2006107945A2 (xx)
ZA (1) ZA200708906B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US7824691B2 (en) * 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
CN102286072B (zh) * 2011-06-27 2013-12-18 中国人民解放军第四军医大学 一种抗金黄色葡萄球菌AgrC群体感应***的AIP多肽衍生物及其应用
WO2017190619A1 (zh) * 2016-05-03 2017-11-09 重程投资管理（上海）有限公司 一种能抑制金葡菌毒素的化学合成环七修饰肽及其应用
CN107998372B (zh) * 2017-11-27 2020-07-31 东南大学 一种抗耐药菌的复合纳米制剂及其制备方法
KR102216319B1 (ko) * 2020-04-10 2021-02-18 주식회사 바이오녹스 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형
JP7505160B2 (ja) * 2020-02-14 2024-06-25 バイオノックス インコーポレイテッド ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN117624301A (zh) * 2022-08-16 2024-03-01 重程投资管理（上海）有限公司 一种体内低毒性的抑制金葡菌毒素产生的合成肽及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
ZM1990A1 (en) 1989-04-27 1991-06-28 Mcneil Ppc Inc Additives to tampons
AU3825995A (en) 1994-10-04 1996-04-26 New York University Blocking expression of virulence factors in s. aureus
US6447786B1 (en) 1994-10-04 2002-09-10 New York University Blocking expression of virulence factors in S. aureus
AU735283B2 (en) 1996-05-22 2001-07-05 New York University Blocking expression of virulence factors in (s. aureus)
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
US6291431B1 (en) * 1997-12-19 2001-09-18 Panorama Research Methods and compositions for the treatment and prevention of Staphylococcal infections
US6747129B1 (en) * 1998-09-15 2004-06-08 The Regents Of The University Of California Target of RNAIII activating protein(TRAP)
EP1188831B1 (en) 1998-09-15 2007-12-05 Naomi Balaban Target of RNAIII activating protein (TRAP)
US6687878B1 (en) * 1999-03-15 2004-02-03 Real Time Image Ltd. Synchronizing/updating local client notes with annotations previously made by other clients in a notes database
WO2001058471A2 (en) * 2000-02-10 2001-08-16 Intermune, Inc. Novel amino acid and peptide inhibitors of staphylococcus virulence
US6706289B2 (en) * 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US20070009566A1 (en) * 2005-04-04 2007-01-11 Naomi Balaban Method and apparatus for treating bacterial infections in devices
US20070015685A1 (en) * 2005-04-04 2007-01-18 Naomi Balaban Bone cement compositions and the like comprising an RNAIII-inhibiting peptide
US7824691B2 (en) * 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
WO2006122127A1 (en) * 2005-05-10 2006-11-16 Naomi Balaban Compositions for administering rnaiii-inhibiting peptides
EP1991245A2 (en) * 2006-02-15 2008-11-19 Massachusetts Institute of Technology (MIT) Medical devices and coatings with non-leaching antimicrobial peptides
WO2007137288A2 (en) * 2006-05-23 2007-11-29 Tufts University Methods and compositions for the treatment and prevention of staphylococcus aureus infections through interference with opuc operon interaction with trap
WO2007147098A2 (en) * 2006-06-16 2007-12-21 Tufts University Identification and use of non-peptide analogs of rnaiii-inhibiting peptide for the treatment of staphylococcal infections
WO2008080218A1 (en) * 2006-12-29 2008-07-10 Osprey Pharmaceuticals Usa, Inc. Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof

Also Published As

Publication number Publication date
CA2603805A1 (en) 2006-10-12
CN101175507A (zh) 2008-05-07
US7824691B2 (en) 2010-11-02
US20070071768A1 (en) 2007-03-29
EP1871405A2 (en) 2008-01-02
IL186375A0 (en) 2008-01-20
JP2008534686A (ja) 2008-08-28
WO2006107945A3 (en) 2007-01-11
WO2006107945A2 (en) 2006-10-12
EP1871405A4 (en) 2009-12-30
AU2006231494A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
IL186375A0 (en) Use of rip in treating staphylococcus aureus infections
GB2424582B (en) Antimicrobial agents
IL187999A0 (en) Compositions for the treatment of persistent infections
AP2007004128A0 (en) Tricyclic-nucleoside compounds for treating viral infections
IL188487A0 (en) Topical skin treating compositions
SI1879877T1 (sl) Protimikrobna sredstva
EP1846411A4 (en) ANTIBACTERIAL ACTIVE SUBSTANCES
EP1796466A4 (en) ANTIBACTERIAL AGENTS
IL184844A0 (en) ??-cyclodextrin derivatives as antibacterial agents
EP1846418A4 (en) ANTIBACTERIAL ACTIVE SUBSTANCES
EP1846417A4 (en) ANTIBACTERIAL ACTIVE SUBSTANCES
EP1773343A4 (en) ANTIBACTERIAL AGENTS
EP1845995A4 (en) ANTIBACTERIAL AGENTS
EP1784410A4 (en) ANTIBACTERIAL AGENTS
EP1846416A4 (en) ANTIBACTERIAL AGENTS
IL179282A0 (en) Altered firbonectin-binding protein of staphylococcus aureus
ZA200704392B (en) Antibiotic combinations for providing total solution to the treatment of infections
GB0513096D0 (en) Treatment of microbial infections
EP1881760A4 (en) ANTIMICROBIAL TREATMENT FOR BACTERIAL INFECTIONS
EP1931209A4 (en) ANTIMICROBIAL SOLUTIONS AND RELATED METHODS
HK1117387A1 (en) Anti-microbial agent
EP2019819A4 (en) INNOVATIVE PEPTIDE DERIVATIVES AS ANTIMICROBIAL AGENTS FOR THE TREATMENT OF INJURIES
GB0407861D0 (en) Antibacterial agents
EP1962864A4 (en) ANTIBACTERIAL AGENTS
ZA200709997B (en) Antimicrobial agents